Mitraclip Secondary Mr denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for mitraclip secondary mr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied MitraClip for Secondary Mitral Regurgitation as Not FDA-Approved

This denial type is factually incorrect on its face for MitraClip in secondary mitral regurgitation. The MitraClip device holds FDA approval that explicitly includes the secondary (functional) MR indication, subject to the anatomical and clinical criteria defined in the labeling. A "not FDA-approved" denial in this context typically results from one of three documentation errors: (1) the prior authorization submission did not reference the correct FDA indication, (2) the reviewer applied criteria for the primary MR indication rather than the secondary MR indication, or (3) the plan's internal database has not been updated to reflect the secondary MR approval.

## Why This Denial Is Appealable

This is among the most straightforward denials to rebut: the appeal simply needs to place the FDA labeling in front of the reviewer and confirm that your proposed use matches the approved indication. You do not need to argue clinical standards of care — you only need to establish the factual record that FDA approval exists and that your case fits within it. Confirm with your cardiologist that your anatomy and clinical status meet the criteria stated in the FDA-approved Instructions for Use (IFU) before submitting.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Decisions due within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, request independent external review within approximately four months. An IRO will independently verify the FDA-approval status.
• Expedited review: If clinically urgent, expedited review typically resolves within 72 hours.
• State regulators: A factually incorrect denial (denying an FDA-approved use) may also be reportable to your state insurance commissioner as a bad-faith denial.

## Documentation to Gather

1. FDA Instructions for Use (IFU): The current MitraClip IFU from the FDA device database, showing the secondary MR indication and its specific criteria — publicly available from the FDA 510(k)/PMA database. 2. Prescriber attestation: A letter from your interventional cardiologist or structural heart specialist confirming that your proposed use matches the FDA-approved indication and that your anatomy and clinical status satisfy the IFU criteria. 3. Echocardiogram report: Imaging documentation confirming the diagnosis of secondary MR and the anatomical parameters your cardiologist deems relevant to IFU eligibility. 4. Denial letter with cited basis: Keep a copy of the denial; the appeal should directly quote and rebut the specific language used to claim non-approval.

## Criteria-Mapping Structure

The appeal letter should be concise and direct for this denial type:

| Denial Claim | Rebuttal | Document | |---|---|---| | MitraClip not FDA-approved for secondary MR | FDA approval is in effect for this indication | IFU cover page + indication section | | Proposed use outside approved parameters | Patient anatomy/clinical status matches IFU criteria | Prescriber attestation + echo report | | Missing prior auth documentation | Clinical summary attached | PA submission package |

Include the FDA IFU as a direct exhibit — not a summary — so there is no ambiguity about what the agency approved. This denial should be reversed at the internal appeal stage.